We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-4.34%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.17B
AUM Growth
+$167M
(+17%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
21.92%
Top 10 Holdings %
Top 10 Hldgs %
3.75%
Holding
2,064
New
608
Increased
491
Reduced
336
Closed
627
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolve Group
RVLV
|
+$4.47M |
| 2 |
AES
AES
|
+$4.1M |
| 3 |
Dollar General
DG
|
+$4.08M |
| 4 |
MOMO
Hello Group
MOMO
|
+$4.03M |
| 5 |
Constellation Brands
STZ
|
+$3.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
e.l.f. Beauty
ELF
|
+$4.49M |
| 2 |
Copa Holdings
CPA
|
+$3.78M |
| 3 |
Idexx Laboratories
IDXX
|
+$2.94M |
| 4 |
Cardlytics
CDLX
|
+$2.79M |
| 5 |
Sonos
SONO
|
+$2.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.28% |
| 2 | Consumer Discretionary | 13.84% |
| 3 | Technology | 13.57% |
| 4 | Financials | 11.67% |
| 5 | Industrials | 11.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Alaunos Therapeutics
TCRT
$4.86M
| $75K | 0.01% |
3,797
-6,082
| -62% | -$262K |
|
|
KRON
1402
DELISTED
Kronos Bio
KRON
| $71K | 0.01% |
54,521
-231,644
| -81% | -$374K |
|
|
RENT
1403
Rent the Runway
RENT
$124M
| $71K | 0.01% |
5,239
-12,550
| -71% | -$358K |
|
1404
Sight Sciences
SGHT
$412M
| $69K | 0.01% |
20,386
-242
| -1% | -$1.59K |
|
1405
McEwen Inc
MUX
$1.18B
| $67K | 0.01% |
+10,251
| New | +$77.3K |
|
|
DHC
1406
Diversified Healthcare Trust
DHC
$2.14B
| $65K | 0.01% |
33,567
-376,523
| -92% | -$955K |
|
1407
Epsilon Energy
EPSN
$173M
| $65K | 0.01% |
+12,229
| New | +$68.1K |
|
1408
Delcath Systems
DCTH
$524M
| $63K | 0.01% |
+15,590
| New | +$73.1K |
|
|
DNMR
1409
DELISTED
Danimer Scientific, Inc.
DNMR
| $63K | 0.01% |
764
+358
| +88% | +$32.5K |
|
|
NUTX
1410
Nutex Health
NUTX
$1.11B
| $62K | 0.01% |
+2,025
| New | +$97.7K |
|
|
ASXC
1411
DELISTED
Asensus Surgical, Inc.
ASXC
| $61K | 0.01% |
225,538
-675,670
| -75% | -$246K |
|
1412
Outlook Therapeutics
OTLK
$191M
| $57K | ﹤0.01% |
+12,970
| New | +$287K |
|
1413
Praxis Precision Medicines
PRAX
$10.1B
| $57K | ﹤0.01% |
2,237
+1,417
| +173% | +$26.8K |
|
1414
Altisource Portfolio Solutions
ASPS
$65.8M
| $53K | ﹤0.01% |
+1,659
| New | +$62.4K |
|
1415
Caribou Biosciences
CRBU
$164M
| $51K | ﹤0.01% |
+10,734
| New | +$66.6K |
|
1416
Lyell Immunopharma
LYEL
$360M
| $51K | ﹤0.01% |
+1,727
| New | +$82K |
|
1417
Sabre
SABR
$835M
| $51K | ﹤0.01% |
+11,358
| New | +$51.5K |
|
1418
Byrna Technologies
BYRN
$101M
| $50K | ﹤0.01% |
22,229
-93,257
| -81% | -$333K |
|
1419
Abeona Therapeutics
ABEO
$413M
| $49K | ﹤0.01% |
+11,638
| New | +$44K |
|
1420
Rackspace Technology
RXT
$1.24B
| $49K | ﹤0.01% |
+20,855
| New | +$47.3K |
|
1421
Clean Energy Fuels
CLNE
$346M
| $48K | ﹤0.01% |
+12,573
| New | +$56K |
|
|
IRD
1422
Opus Genetics
IRD
$302M
| $46K | ﹤0.01% |
+13,588
| New | +$54.6K |
|
|
ATYR
1423
aTyr Pharma
ATYR
$50.1M
| $44K | ﹤0.01% |
+27,559
| New | +$51K |
|
|
AMRN
1424
Amarin Corp
AMRN
$303M
| $42K | ﹤0.01% |
2,284
-2,234
| -49% | -$48.4K |
|
1425
Companhia Siderúrgica Nacional
SID
$1.23B
| $42K | ﹤0.01% |
+17,380
| New | +$44.5K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q3 2023 Portfolio in Review
As of Q3 2023, GSA Capital Partners held 2,064 positions worth $1.17B, up 17% from $1B the previous quarter. Its ten largest holdings account for 3.8% of the portfolio.
GSA Capital Partners deployed $256M of net new capital in Q3 2023, opening 608 new positions and adding to 491 existing holdings. Its largest new stake was Revolve Group: 280,700 shares worth $3.82M.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Cardlytics, an estimated $2.79M trimmed.
- GSA Capital Partners's largest Q3 2023 buy was Revolve Group: 280,700 shares worth $3.82M.
- GSA Capital Partners added most to Hello Group in Q3 2023, an estimated $4.03M increase.
- GSA Capital Partners's biggest Q3 2023 reduction was Cardlytics, cutting an estimated $2.79M.
- GSA Capital Partners fully exited e.l.f. Beauty in Q3 2023, selling an estimated $4.49M.
- GSA Capital Partners's ten largest holdings make up 3.8% of its $1.17B portfolio in Q3 2023.
- GSA Capital Partners opened 608 new positions and closed 627 in Q3 2023.
- GSA Capital Partners's portfolio value rose 17% quarter-over-quarter to $1.17B.
Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.